Overview

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Status:
Completed
Trial end date:
2016-12-27
Target enrollment:
Participant gender:
Summary
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.
Phase:
Phase 1
Details
Lead Sponsor:
Enanta Pharmaceuticals
Collaborator:
Novotech (Australia) Pty Limited